Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05336409 · ClinicalTrials.gov registry record · Phase 1
A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies
A Phase 1 study, sponsored by Century Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT05336409 is a Phase 1 study that was terminated before completion, run by Century Therapeutics. The registered enrollment target is 28 participants.
The verdict
NCT05336409, a Phase 1 study, was terminated before completion, sponsored by Century Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
ELiPSE-1 is a Phase 1, multi-center, dose-finding study to evaluate the safety, pharmacokinetics, and preliminary efficacy of CNTY-101 in participants with relapsed or refractory cluster of differentiation (CD)19-positive B-cell malignancies.
Interventions
- BIOLOGICAL CNTY-101
- BIOLOGICAL IL-2
- DRUG Lymphodepleting Chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2023-01-24 |
| Est. Completion | 2025-07-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05336409
The ClinicalTrials.gov registry entry for NCT05336409 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Century Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which CNTY-101 is the first listed.
NCT05336409 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05336409 about?
NCT05336409 is a clinical study titled "A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies". ELiPSE-1 is a Phase 1, multi-center, dose-finding study to evaluate the safety, pharmacokinetics, and preliminary efficacy of CNTY-101 in participants with relapsed or refractory cluster of differentiation (CD)19-positive B-cell malignancies.
What is the current status of trial NCT05336409?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2023-01-24. Estimated completion is 2025-07-01.
What interventions are being tested in trial NCT05336409?
The interventions under investigation include: CNTY-101 (BIOLOGICAL), IL-2 (BIOLOGICAL), Lymphodepleting Chemotherapy (DRUG).
Who is sponsoring clinical trial NCT05336409?
This trial is sponsored by Century Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.